Reduction of hepatic glucocortocoid receptor and hexose-6-phosphate dehydrogenase expression ameliorates diet-induced obesity and insulin resistance in mice

Journal of Molecular Endocrinology

Volumn 41, Issue 1-2, 2008, Pages 53-64

  Liu, Yanjun ^a   Nakagawa, Yuichi ^b   Wang, Ying ^a   Liu, Limei ^c   Du, Hongwei ^d   Wang, Wei ^a   Ren, Xiuhai ^a   Lutfy, Kabirullah ^a,e   Friedman, Theodore C ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d JILIN UNIVERSITY   (China)

^e WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CARBENOXOLONE; DEOXYGLUCOSE; GLUCOCORTICOID RECEPTOR; GLUCOSE 6 PHOSPHATASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; LIVER ENZYME; MESSENGER RNA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); 11BETA HYDROXYSTEROID DEHYDROGENASE 1; CORTICOSTERONE; GALACTOSE 6 PHOSPHATE DEHYDROGENASE; GALACTOSE-6-PHOSPHATE DEHYDROGENASE; INSULIN; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION FUNCTION; DIET; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVITY; GENE EXPRESSION; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; LIVER CELL CULTURE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; FAT INTAKE; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; IMMUNOBLOTTING; LIVER; LIVER CELL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CARBENOXOLONE; CARBOHYDRATE DEHYDROGENASES; CELLS, CULTURED; CORTICOSTERONE; DEOXYGLUCOSE; DIETARY FATS; GENE EXPRESSION; GLUCOSE TOLERANCE TEST; HEPATOCYTES; HOMEOSTASIS; IMMUNOBLOTTING; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, INBRED C57BL; OBESITY; RECEPTORS, GLUCOCORTICOID; RNA, MESSENGER;

EID: 51349085477     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/JME-08-0004     Document Type: Article

References (51)

1. Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingstrom G, Larsson C, Forsgren M, Ashkzari M et al. 2003 Selective inhibition of 11 β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144 4755-4762.
2. Andrews RC, Rooyackers O & Walker BR 2003 Effects of the 11 β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 88 285-291.
3. Aoki K, Homma M, Hirano T, Oka K, Satoh S, Mukasa K, Ito S & Sekihara H 2001 MRNA and enzyme activity of hepatic 11 β-hydroxysteroid dehydrogenase type 1 are elevated in C57BL/KsJ-db/db mice. Life Sciences 69 2543-2549.
4. Atanasov AG, Nashev LG, Schweizer RA, Frick C & Odermatt A 2004 Hexose-6-phosphate dehydrogenase determines the reaction direction of 11β-hydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Letters 571 129-133.
5. Banhegyi G, Benedetti A, Fulceri R & Senesi S 2004 Cooperativity between 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase in the lumen of the endoplasmic reticulum. Journal of Biological Chemistry 279 27017-27021.
6. Bujalska IJ, Kumar S & Stewart PM 1997 Does central obesity reflect 'Cushing's disease of the omentum'? Lancet 349 1210-1213.
7. Carson-Jurica MA, Schrader WT & O'Malley BW 1990 Steroid receptor family: structure and functions. Endocrine Reviews 11 201-220.
8. Chapman KE & Seckl JR 2008 11β-HSD1, inflammation, metabolic disease and age related cognitive (dys)function. (Epub ahead of print) Neurochemical Research 33 624-636.
9. Chou JY, Matern D, Mansfield BC & Chen YT 2002 Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Current Molecular Medicine 2 121-143.
10. Csala M, Bánhegyi G & Benedetti A 2006 Endoplasmic reticulum: a metabolic compartment. FEBS Letters 580 2160-2165.
11. Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, Lavery GG, Bedendo O, Ray DW, Laing I et al. 2003 Mutations in the genes encoding 11 β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nature Genetics 34 434-439.
12. Ferguson SE, Pallikaros Z, Michael AE & Cooke BA 1999 The effects of different culture media, glucose, pyridine nucleotides and adenosine on the activity of 11β-hydroxysteroid dehydrogenase in rat Leydig cells. Molecular and Cellular Endocrinology 158 37-44.
13. Friedman JE, Yun JS, Patel YM, McGrane MM & Hanson RW 1993 Glucocorticoids regulate the induction of phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes. Journal of Biological Chemistry 268 12952-12957.
14. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS et al. 2005 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. Journal of Experimental Medicine 202 517-527.
15. Hewitt KN, Walker EA & Stewart PM 2005 Minireview: hexose-6-phosphate dehydrogenase and redox control of 11beta-hydroxy-steroid dehydrogenase type 1 activity. Endocrinology 146 2539-2543.
16. Hino Y & Minakami S 1982 Hexose-6-phosphate and 6-phosphogluconate dehydrogenases of rat liver microsomes. Involvement in NADPH and carbon dioxide generation in the luminal space of microsomal vesicles. Journal of Biochemistry 92 547-557.
17. Ho RC, Alcazar O, Fujii N, Hirshman MF & Goodyear LJ 2004 p38MAPK regulation of glucose transporter expression and glucose uptake in L6 myotubes and mouse skeletal muscle. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 286 R342-R349.
18. Jamieson PM, Chapman KE, Edwards CR & Seckl JR 1995 11beta-hydroxysteroid dehydrogenase is an exclusive 11 β-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 136 4754-4761.
19. Jenson M, Kilroy G, York DA & Braymer D 1996 Abnormal regulation of hepatic glucocorticoid receptor mRNA and receptor protein distribution in the obese Zucker rat. Obesity Research 4 133-143.
20. Kimura K, Endou H, Sudo J & Sakai F 1979 Glucose dehydrogenase (hexose 6-phosphate dehydrogenase) and the microsomal electron transport system. Evidence supporting their possible functional relationship. Journal of Biochemistry 85 319-326.
21. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR et al. 1997 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. PNAS 94 14924-14929.
22. Lavery GG, Walker EA, Draper N, Jeyasuria P, Marcos J, Shackleton CH, Parker KL, White PC & Stewart PM 2006 Hexose-6-phosphate dehydrogenase knock-out mice lack 11β-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. Journal of Biological Chemistry 281 6546-6551.
23. Liu YJ, Nakagawa Y & Ohzeki T 1998 Gene expression of 11β-hydroxysteroid dehydrogenase type 1 and type 2 in the kidneys of insulin-dependent diabetic rats. Hypertension 31 885-889.
24. Liu Y, Nakagawa Y, Wang Y, Li R, Li X, Ohzeki T & Friedman TC 2003 Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice. Diabetes 52 1409-1416.
25. Liu Y, Nakagawa Y, Wang Y, Sakurai R, Tripathi PV, Lutfy K & Friedman TC 2005 Increased glucocorticoid receptor and 11β-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice. Diabetes 54 32-40.
26. Liu Y, Yan C, Wang Y, Nakagawa Y, Nerio N, Anghel A, Lutfy K & Friedman TC 2006 Liver X receptor agonist T0901317 inhibition of glucocorticoid receptor expression in hepatocytes may contribute to the amelioration of diabetic syndrome in db/db mice. Endocrinology 147 5061-5068.
27. Livingstone DE & Walker BR 2003 Is 11β-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats Journal of Pharmacology and Experimental Therapeutics 305 167-172.
28. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR & Flier JS 2001 A transgenic model of visceral obesity and the metabolic syndrome. Science 294 2166-2170.
29. McCormick KL, Wang X & Mick GJ 2006 Evidence that the 11 β-hydroxysteroid dehydrogenase (11β-HSD1) is regulated by pentose pathway flux. Studies in rat adipocytes and microsomes. Journal of Biological Chemistry 281 341-347.
30. Monder C, Stewart PM, Laksmi V, Valentino R, Burt D & Edwards CR 1989 Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology 125 1046-1053.
31. Nammi S, Dembele K & Nyomba BLG 2007 Increased 11beta-hydroxysteroid dehydrogenase type-1 and hexose-6-phosphate dehydrogenase in liver and adipose tissue of rat offspring exposed to alcohol in utero. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 292 R1101-R1109.
32. Nuotio-Antar AM, Hachey D & Hasty AH 2007 Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. American Journal of Physiology. Endocrinology and Metabolism 293 E1517-E1528.
33. Okada S, York DA & Bray GA 1992 Mifepristone (RU486), a blocker of type II glucocorticoid and progestin receptors, reverses a dietary form of obesity. American Journal of Physiology 262 R1106-R1110.
34. Opherk C, Tronche F, Kellendonk C, Kohlmuller D, Schulze A, Schmid W & Schutz G 2004 Inactivation of the glucocorticoid receptor in hepatocytes leads to fasting hypoglycemia and ameliorates hyperglycemia in streptozotocin-induced diabetes mellitus. Molecular Endocrinology 18 1346-1353.
35. Rizza RA, Mandarino LJ & Gerich JE 1982 Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. Journal of Clinical Endocrinology and Metabolism 54 131-138.
36. Ropson IJ & Powers DA 1998 A novel dehydrogenase reaction mechanism for hexose-6-phosphate dehydrogenase isolated from the teleost Fundulus heteroclitus. Journal of Biological Chemistry 263 11697-11703.
37. Rosen J & Miner JN 2005 The search for safer glucocorticoid receptor ligands. Endocrine Reviews 26 452-464.
38. Saegusa H, Nakagawa Y, Liu YJ & Ohzeki T 1999 Influence of placental 11β-hydroxysteroid dehydrogenase (11β-HSD) inhibition on glucose metabolism and 11β-HSD regulation in adult offspring of rats. Metabolism 48 1584-1588.
39. Sartor O & Cutler GB Jr 1996 Mifepristone: treatment of Cushing's syndrome. Clinical Obstetrics and Gynecology 39 506-510.
40. Schuster D, Maurer EM, Laggner C, Nashev LG, Wilckens T, Langer T & Odermatt A 2006 The discovery of new 11β-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. Journal of Medicinal Chemistry 12 3454-3466.
41. Schweizer RA, Zürcher M, Balazs Z, Dick B & Odermatt A 2004 Rapid hepatic metabolism of 7-ketocholesterol by 11β-hydroxysteroid dehydrogenase type 1. Journal of Biological Chemistry 279 18415-18424.
42. Seckl JR, Cleasby M & Nyirenda MJ 2000 Glucocorticoids, 11β-hydroxysteroid dehydrogenase, and fetal programming. Kidney International 57 1412-1417.
43. Stafford JM, Wilkinson JC, Beechem JM & Granner DK 2001 Accessory factors facilitate the binding of glucocorticoid receptor to the phosphoenolpyruvate carboxykinase gene promoter. Journal of Biological Chemistry 276 39885-39891.
44. Stegeman JJ & Klotz AV 1979 A possible role for microsomal hexose-6-phosphate dehydrogenase in microsomal electron transport and mixed-function oxygenase activity: Biochemical and Biophysical Research Communications 87 410-415.
45. Tomlinson JW, Sherlock M, Hughes B, Hughes SV, Kilvington F, Bartlett W, Courtney R, Rejto P, Carley W & Stewart PM 2007 Inhibition of 11β-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. Journal of Clinical Endocrinology and Metabolism 92 857-864.
46. Walker BR, Connacher AA, Lindsay RM, Webb DJ & Edwards CR 1995 Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. Journal of Clinical Endocrinology and Metabolism 80 3155-3159.
47. Wang SJ, Birtles S, de Schoolmeester J, Swales J, Moody G, Hislop D, O'Dowd J, Smith DM, Turnbull AV & Arch JR 2006 Inhibition of 11β-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia 49 1333-1337.
48. Watts LM, Manchem VP, Leedom TA, Rivard AL, McKay RA, Bao D, Neroladakis T, Monia BP, Bodenmiller DM, Cao JX et al. 2005 Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 54 1846-1853.
49. Welberg LA, Seckl JR & Holmes MC 2000 Inhibition of 11β-hydroxysteroid dehydrogenase, the foeto-placental barrier to maternal glucocorticoids, permanently programs amygdala GR mRNA expression and anxiety-like behaviour in the offspring. European Journal of Neuroscience 12 1047-1054.
50. Whorwood CB, Donovan SJ, Flanagan D, Phillips DI & Byrne CD 2002 Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 51 1066-1075.
51. 2+/ cal-modulin-dependent protein kinase kinase-alpha regulates skeletal muscle glucose uptake independent of AMP-activated protein kinase and Akt activation. Diabetes 56 1403-1409.